The MAPS email address is provided, along with MAPS website addresses for the following functions: general information, enrollment, information requests. and data upload. Contact information is provided for the MAPS Manager and Drug Monitoring Section Analyst. Data for 2017 cover the state population (9,991.177), DEA registered drug prescribers (48,400) and DEA registered drug dispensers (2,594). MAPS available reports are listed. MAPS data for 2018 indicate that its funding sources were the state general fund, controlled substance registration fees, and a Harold Rogers grant. MAPS 2018 personnel numbers are reported for the following job categories: operational (2), technical (2), and analytical (2). Significant MAPS dates pertain to enabling legislation (1988), becoming operational (1989), on-line access (2003), and electronic reporting (2003). Access information is provided for statutes and rules relevant to MAPS policies and procedures. Reporting on monitored drugs is the next business day after prescribing for controlled substances in schedules II, III, IV, and V. Also, hospitals, law enforcement agencies, and emergency medical services must provide naloxone administering information. Naloxone dispensing information must be reported by hospitals and pharmacies. Opioid-related drug overdoses or deaths must be reported by the Michigan Department of Health and Human Services. Drug manufacturers or distributors must report specified drug data quarterly. Lost/stolen prescription drugs must be reported. MAPS miscellaneous capabilities and policies are listed. Enrollment in and use of MAPS is required for prescribers but not dispensers of drugs. Law enforcement agencies' access to MAPS drug data requires that there be an active investigation and subpoena, along with an on-line and written request. Information is provided on MAPS technological capabilities and requestor reports
Prescription Drug Monitoring Program: Michigan State Profile
NCJ Number
253008
Date Published
October 2018
Length
8 pages
Annotation
Information and data are presented for the Michigan prescription drug monitoring program, named the Michigan Automated Prescription System (MAPS), which is administered by the state's Professional Licensing Agency.
Abstract